8-(2-{(cyclopropylmethyl)[(4-methyl-1,3-thiazol-2-yl)methyl]amino}ethyl)-2,2-difluoro[1,3]dioxolo[4,5-h][1,2,4]triazolo[1,5-c]quinazolin-5-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 8-(2-{(cyclopropylmethyl)[(4-methyl-1,3-thiazol-2-yl)methyl]amino}ethyl)-2,2-difluoro[1,3]dioxolo[4,5-h][1,2,4]triazolo[1,5-c]quinazolin-5-amine
• 英文别名: US11046714, Example 60；4-[2-[cyclopropylmethyl-[(4-methyl-1,3-thiazol-2-yl)methyl]amino]ethyl]-12,12-difluoro-11,13-dioxa-3,5,6,8-tetrazatetracyclo[7.7.0.02,6.010,14]hexadeca-1(9),2,4,7,10(14),15-hexaen-7-amine
• 化学式: C₂₁H₂₁F₂N₇O₂S
• 分子量: 473.506
• InChiKey: YPDQSLFPONLXDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  132
• 氢给体数：
  1
• 氢受体数：
  11

文献信息

• [EN] 2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES 2,2-DIFLUORODIOXOLO DU RÉCEPTEUR A2A
  申请人：MERCK SHARP & DOHME

  公开号：WO2015027431A1

  公开（公告）日：2015-03-05

  The present invention is directed to 2,2-difluorodioxolo compounds that are antagonists of A2A receptor. The present invention is also directed to uses of the 2,2-difluorodioxolo compounds described herein in the potential treatment or prevention of neurological disorders and diseases in which A2A receptor are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds and to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which A2A receptors are involved.

  本发明涉及对A2A受体拮抗剂的2,2-二氟二氧杂环己烷化合物。本发明还涉及在潜在治疗或预防涉及A2A受体的神经系统疾病和疾病中使用本文所述的2,2-二氟二氧杂环己烷化合物。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及A2A受体的这些疾病中使用这些药物组合物的用途。
• [EN] 2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS<br/>[FR] 2,2-DIFLUORODIOXOLO ANTAGONISTES DE RÉCEPTEURS A2A
  申请人：MERCK SHARP & DOHME

  公开号：WO2015031221A1

  公开（公告）日：2015-03-05

  The present invention is directed to 2,2-difluorodioxolo compounds that are antagonists of A2A receptor. The present invention is also directed to uses of the 2,2- difluorodioxolo compounds described herein in the potential treatment or prevention of 5 neurological disorders and diseases in which A2A receptor are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds and to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which A2A receptors are involved.

  本发明涉及2,2-二氟二氧杂环丁烷类化合物，其为A2A受体拮抗剂。本发明还涉及在潜在治疗或预防A2A受体参与的神经系统疾病和疾病中使用本文描述的2,2-二氟二氧杂环丁烷类化合物。本发明还涉及含有这些化合物的药物组合物以及这些药物组合物在预防或治疗A2A受体参与的相关疾病中的用途。
• 2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS
  申请人：ALI Amjad

  公开号：US20160214997A1

  公开（公告）日：2016-07-28

  The present invention is directed to 2,2-difluorodioxolo compounds that are antagonists of A 2A receptor. The present invention is also directed to uses of the 2,2-difluorodioxolo compounds described herein in the potential treatment or prevention of neurological disorders and diseases in which A 2A receptor are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds and to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which A 2A receptors are involved.

  本发明涉及2,2-二氟二氧杂环己烷化合物，其为A2A受体拮抗剂。本发明还涉及使用本说明书中描述的2,2-二氟二氧杂环己烷化合物潜在地治疗或预防神经系统疾病和疾病，其中涉及A2A受体。本发明还涉及包含这些化合物的制药组合物以及使用这些制药组合物预防或治疗涉及A2A受体的这些疾病。
• 2,2-difluorodioxolo A2A receptor antagonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US11046714B2

  公开（公告）日：2021-06-29

  The present invention is directed to 2,2-difluorodioxolo compounds that are antagonists of A2A receptor. The present invention is also directed to uses of the 2,2-difluorodioxolo compounds described herein in the potential treatment or prevention of neurological disorders and diseases in which A2A receptor are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds and to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which A2A receptors are involved.

  本发明涉及作为 A2A 受体拮抗剂的 2,2-二氟二恶茂化合物。本发明还涉及本文所述 2,2-二氟二恶茂化合物在潜在治疗或预防涉及 A2A 受体的神经紊乱和疾病中的用途。本发明还涉及包含这些化合物的药物组合物，以及这些药物组合物在预防或治疗涉及 A2A 受体的此类疾病中的用途。